NEURBIOLOGICAL TECHNOLOGIES INITIATES SECOND VIPRINEX TRIAL

A A

Neurbiological Technologies has announced the initiation of its second Phase III study of Viprinex (Ancrod) in patients with acute ischemic stroke.

The overall clinical development program for both trials will enroll 1,300 patients, divided equally between the two trials. The program will be global in nature, recruiting patients in the U.S, Europe, the Pacific Rim, and South Africa.